1. Home
  2. NIO vs RPRX Comparison

NIO vs RPRX Comparison

Compare NIO & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NIO
  • RPRX
  • Stock Information
  • Founded
  • NIO 2014
  • RPRX 1996
  • Country
  • NIO China
  • RPRX United States
  • Employees
  • NIO N/A
  • RPRX N/A
  • Industry
  • NIO Auto Manufacturing
  • RPRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • NIO Consumer Discretionary
  • RPRX Health Care
  • Exchange
  • NIO Nasdaq
  • RPRX Nasdaq
  • Market Cap
  • NIO 12.1B
  • RPRX 11.8B
  • IPO Year
  • NIO 2018
  • RPRX 2020
  • Fundamental
  • Price
  • NIO $4.50
  • RPRX $25.70
  • Analyst Decision
  • NIO Buy
  • RPRX Strong Buy
  • Analyst Count
  • NIO 11
  • RPRX 6
  • Target Price
  • NIO $7.49
  • RPRX $41.67
  • AVG Volume (30 Days)
  • NIO 54.3M
  • RPRX 2.5M
  • Earning Date
  • NIO 11-20-2024
  • RPRX 11-06-2024
  • Dividend Yield
  • NIO N/A
  • RPRX 3.27%
  • EPS Growth
  • NIO N/A
  • RPRX 518.56
  • EPS
  • NIO N/A
  • RPRX 2.55
  • Revenue
  • NIO $8,741,599,705.00
  • RPRX $2,266,003,000.00
  • Revenue This Year
  • NIO $32.15
  • RPRX $12.38
  • Revenue Next Year
  • NIO $45.14
  • RPRX $11.26
  • P/E Ratio
  • NIO N/A
  • RPRX $10.06
  • Revenue Growth
  • NIO 30.94
  • RPRX N/A
  • 52 Week Low
  • NIO $3.61
  • RPRX $25.10
  • 52 Week High
  • NIO $9.57
  • RPRX $31.66
  • Technical
  • Relative Strength Index (RSI)
  • NIO 36.72
  • RPRX 30.45
  • Support Level
  • NIO $4.86
  • RPRX $26.08
  • Resistance Level
  • NIO $5.23
  • RPRX $28.36
  • Average True Range (ATR)
  • NIO 0.21
  • RPRX 0.60
  • MACD
  • NIO -0.08
  • RPRX -0.13
  • Stochastic Oscillator
  • NIO 8.71
  • RPRX 18.40

About NIO NIO Inc. American depositary shares each representing one ordinary share

Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold over 160,000 EVs in 2023, accounting for about 2% of the China passenger new energy vehicle market.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: